Navigation Links
Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at,the Fourth International Conference on Tumor Microenvironment in,Florence, Italy

tary DOS47 new drug candidate with a highly specific single domain antibody, to form a potential new targeted drug product for the treatment of adenocarcinoma of the lung, the most common form of cancer in the world today. L-DOS47 is thought to function by leveraging a
natural process in the body called the urea cycle, to produce an anti-cancer effect. It is based upon a naturally occurring enzyme called urease that essentially reverses the urea cycle by breaking down urea into metabolites that include ammonia and hydroxyl ions. By doing so at the site of cancerous tissues in the body, L-DOS47 is believed to modify the microenvironmental conditions of lung cancer cells in a manner that leads to their death. Among these theorized effects, L-DOS47 is believed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra-cellular conditions that are known to be necessary for cancer cell survival. As well, the local production of ammonia at the site of cancerous tissues is thought to readily diffuse into the cancer cells to exert a potent cytotoxic effect by interfering with their critical metabolic functions.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b, for the treatment of conditions caused by the human papilloma virus, and its novel L-DOS47 new drug product candidate for the treatment of lung adenocarcinoma. Helix is listed on the TSX under the symbol "HBP".

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. Helix disclaims responsibility for information contained in the Tu
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
2. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
5. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
7. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
8. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
9. The Past, Present and Future of HLA Typing
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:12/24/2014)... PRINCETON, N.J. , Dec. 24, 2014 /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today that on ... registered public offering. The Company raised ... offering and intends to use the net proceeds ...
(Date:12/24/2014)... and LONDON , December 24, 2014 ... are expected to grow at an average rate of ... value and volume. Hip, knee and spine surgeries are ... in emerging economies they have a lower penetration. Increased ... the use of composites. Non-metallic orthopedic devices have gained ...
(Date:12/24/2014)... 2014 LifeScienceIndustryResearch.com adds ... Syringe Industry of 178 pages providing 10 ... library. The 2014 Market Research ... a professional and deep research report on ... the report introduces Disposable Syringe basic information ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... , May 8 Inverness Medical Innovations, Inc. (NYSE: ... take charge of their health at home through the merger of ... the Bank of America Merrill Lynch Health Care Conference being held ... in New York, New York .  Jon Russell, Vice President, ...
... SWANTON, Vt ., May 7 This May, ... in their effort to spread Multiple Chemical Sensitivity Syndrome awareness.   , ... AllerAir will make chemical awareness ... at www.allerair.com .  Additionally, their blogs and articles ...
Cached Medicine Technology:Multiple Chemical Sensitivities Are Real 2Multiple Chemical Sensitivities Are Real 3
(Date:12/25/2014)... (PRWEB) December 25, 2014 BambooFlooringChina.com sells ... high quality bamboo flooring. Today, the company announces ... in many styles and colors. , BambooFlooringChina.com is the ... CEO, the promotion is valid until Jan. 20, 2015. ... strips and woven with a natural thread. All the ...
(Date:12/25/2014)... FL (PRWEB) December 25, 2014 When head ... find themselves in a frenzy to get rid of it ... But families in Coral Gables now have the solution right ... second salon clinic location, Lice Troopers provides full spectrum head ... the Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... children with complex chronic illnesses can receive effective, less expensive ... with easy access to a team of dedicated health care ... to become seriously ill and need either hospitalization or a ... an enhanced medical home clinic at the University of Texas ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Overeating is common during the holidays, ... moderation, an expert says. "Don,t arrive at a party ... you know you,ll be attending a party, but deprivation leads ... dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., said ... healthy during the day and even to have a snack ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
Breaking Medicine News(10 mins):Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3
... Ammonia gas leaked from the state-owned Fertilisers and Chemicals Travancore ... breathing problems among local residents. The factory said later the ... leak was detected around 8 p.m. and was rectified. ... locals found it difficult to breathe. ,TV reporters ...
... People who use Swedish moist snuff (snus) run twice the ... main result of a follow-up study conducted by Karolinska ... is published today online in the prestigious medical journal The ... for pancreatic cancer, which is an unusually malignant form of ...
... on a racing heartbeat. ,Researchers at ... 11 issue of Circulation Research how an enzyme acts on ... heart's "fight-or-flight" reaction to adrenaline. ,A single cell ... pace of the beating heart, triggering its neighbor cells to ...
... central government is aiming for 100 percent registration of births ... Act 1969 that would simplify the process, an official ... issue as this helps in maintaining a record for a ... birth registration record is 64 percent as some of the ...
... of births by 2010 by amending the Registration of Birth ... an official said Friday. ,'Registration at birth is ... for a person for his or her lifetime. In India, ... of the states have still not implemented it properly,' D.K. ...
... a single sphere in the US they would like to ... is the cooked chickens market. ,The U.S. ... to familiarize the U.S. market with its cooked chickens." ... about such common practices among Chinese farmers, like flooding crops ...
Cached Medicine News:Health News:Use of Swedish 'snus' is Linked to a Doubled Risk of Pancreatic Cancer 2Health News:Slowing the Racing Heart 2Health News:Government to Amend Birth Registration Act 2Health News:Government to Amend Birth Registration Act 2Health News:China Eyeing US Cooked Chickens Market 2
Family Practice: Letter Acuity, Astigmatic,Clock, Tumbling E, and Allen Tests....
Acuity Astigmatism: Letter Acuity, Astigmatic Clock, Number Acuity, and Tumbling E Tests....
... called the Prostate Specific Antigen (total PSA) test, ... to manage patients with prostate cancer. Of the ... test, was the first approved for the detection ... digital rectal examination (DRE) in men aged 50 ...
... Smile Tests at 480 and 120 ... for children of 6,months to 5 years ... ,Stereo Smile Tests screen for:, Amblyopia, Strabismus, ... Test Includes:, 1 demonstration card, 1 pair ...
Medicine Products: